Up next

Autoplay

Apalutamide Plus ADT in Older Patients With mCSPC, nmCRPC

1 Views • 08/29/25
Share
Side Effects
Side Effects
Subscribers
0

John Shen, MD, University of California, Los Angeles, and Julie N. Graff, MD, OHSU Knight Cancer Institute, discuss a recent study they co-authored on the effects of apalutamide treatment by patient age for those with mCSPC and nmCRPC. Together, they analyze the outcomes of patients who were involved in the TITAN and SPARTAN trials as well as the significance of assessing functional age over chronological age in treatment decision-making.

Show more
0 Comments sort Sort By

Up next

Autoplay